ClinicalTrials.gg
TerminatedNCT02224235Updated Oct 6, 2020

COBRA SHIELD OCT Study

An interventional study of Aspirin and Resolute Integrity DES in Stable Angina, sponsored by CeloNova BioSciences, Inc.. Terminated at 2 sites in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.

Sponsored by CeloNova BioSciences, Inc. · Not applicable, Interventional, and Treatment

Why this study was terminated
Inadequate enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase one of this study is a prospective, randomized (2:1), pilot study that will evaluate COBRA PzF vascular healing patterns and thrombus formation with Optical Coherence Tomography (OCT) at 3 months after stent implantation in comparison with Resolute Integrity drug eluting stent (DES). Patients in the COBRA PzF (Group 1) will receive dual anti platelets for one week followed by aspirin, while patients implanted with ZES (Group 2), will receive Dual anti-platelet therapy (DAPT) for at least 6 months followed by aspirin.

After the completion of Phase 1, Phase 2 will enroll 10 patients in the COBRA PzF (Group 3). Patients in Group 3 will receive aspirin alone and have OCT at one month after the stent procedure to evaluate COBRA PzF vascular healing patterns and thrombus formation at one month follow up.

Read the detailed description

Phase one of this study is a prospective, randomized (2:1), pilot study that will evaluate COBRA PzF vascular healing patterns and thrombus formation with Optical Coherence Tomography (OCT) at 3 months after stent implantation in comparison with Resolute Integrity drug eluting stent (DES). Patients in the COBRA PzF (Group 1) will receive dual anti platelets for one week followed by aspirin, while patients implanted with ZES (Group 2), will receive Dual anti-platelet therapy (DAPT) for at least 6 months followed by aspirin.

After the completion of Phase 1, Phase 2 will enroll 10 patients in the COBRA PzF (Group 3). Patients in Group 3 will receive aspirin alone and have OCT at one month after the stent procedure to evaluate COBRA PzF vascular healing patterns and thrombus formation at one month follow up.

This study was terminated after enrollment of 8 patients due to insufficient enrollment

02

Conditions studied

  • Stable Angina

Browse trials for

Keywords

  • Stable angina
  • PCI
  • Percutaneous Coronary Intervention
03

In context

Angina, Stable

344 studies on the registry are indexed under Angina, Stable; 57 are open to participants now.

This study's enrollment of 8 is below the median of 150 across 231 interventional studies indexed under Angina, Stable.

Browse Angina, Stable studies →

Lead sponsor

CeloNova BioSciences, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient >= 18 years old.
  • Eligible for percutaneous coronary intervention (PCI).
  • Patient provides written .
  • Patient is willing to comply with follow-up evaluation.
  • Acceptable candidate for coronary artery bypass graft (CABG) surgery.
  • Stable angina pectoris or a positive functional ischemia study.
  • Male or non-pregnant female patient
  • Patient indicated for elective stenting of up to 2 stenotic lesions in two separate native coronary arteries.
  • Reference vessel >=2.5 mm and\<= 4.0 mm in diameter by visual estimate.
  • Target lesion \<=20 mm in length by visual estimate.
  • Protected left main lesion with >50% stenosis.
  • Target lesion stenosis >= 70% and \< 100% by visual estimate OR Target lesion stenosis \<70% who meet physiological criteria for revascularization (i.e. positive Fractional Flow Reserve).

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in another device or drug trial.
  • Previously enrolled in another stent trial within the prior 2 years.
  • ANY planned elective surgery or percutaneous intervention within the subsequent 3 months.
  • A previous coronary interventional procedure of any kind within 30 days prior to the procedure.
  • The patient requires staged procedure of either the target or any non-target vessel before OCT procedure at 3 months post-procedure.
  • The target lesion requires treatment with a device other than percutaneous transluminal coronary angioplasty (PTCA) prior to stent placement.
  • Previous drug eluting stent (DES) or bare metal stent (BMS) deployment anywhere in the target vessel.
  • Co-morbid condition(s) that could limit the patient's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.
  • Concurrent medical condition with a of less than 12 months.
  • Documented (LVEF) \< 50% at the most recent evaluation.
  • Patients with diagnosis of myocardial infarction (MI) within 72 hours (i.e. CK-MB must be returned to normal prior to enrollment) or suspected acute MI at time of enrollment.
  • Previous intervention in the target vessel.
  • History of cerebrovascular accident or in the last 6 months.
  • Leukopenia (leukocytes \< 3.5 x10\^9 / liter).
  • Neutropenia ( \< 1000/mm3) \<= 3 days prior to enrollment.
  • Thrombocytopenia ( \< 100,000/mm3) pre-procedure.
  • Active peptic ulcer or active GI bleeding.
  • History of bleeding diathesis or coagulopathy or inability to accept blood transfusions.
  • Known or to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, L-605 Cobalt chromium alloy or sensitivity to contrast media, which cannot be adequately pre-medicated.
  • Serum creatinine level > 2.0 mg/dl within 7 days prior to index procedure.
  • Patients not responsive to Plavix/ aspirin and or unable to tolerate Plavix/ aspirin for 6 month post procedure.
  • Patient on or may require anticoagulation therapy within 3 months of index procedure.
  • Flow limiting dissections observed on OCT
  • Significant tissue prolapse within the stent observed on OCT
  • Unprotected left main coronary artery disease
  • Target vessel with any lesions with greater than 60% diameter stenosis outside of a range of 5 mm proximal and distal to the target lesion based on visual estimate or on-line quantitative coronary arteriography (QCA).
  • Target lesion (or vessel) exhibiting an intraluminal thrombus (occupying > 50% of the true lumen diameter) at any time.
  • Lesion location that is aorto-ostial or within 5 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX).
  • Target lesion with side branches > 2.0mm in diameter.
  • Target vessel is excessively tortuous (two bends > 90˚ to reach the target lesion).
  • Target lesion is severely calcified.
  • Thrombolysis In Myocardial Infarction (TIMI) flow 0 or 1
  • Target lesion is in a bypass graft
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Group 1- COBRA 1 week DAPT

    COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week

    Device: COBRA PzF · Drug: DAPT

  • Active comparator
    Group 2 - DES 6 month DAPT

    Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months

    Device: Resolute Integrity DES · Drug: DAPT

  • Experimental
    Group 3 - COBRA Aspirin

    COBRA PzF coronary stent followed by aspirin alone

    Drug: Aspirin · Device: COBRA PzF

Interventions

  • 75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)

    Also known as: Ascriptin Enteric, Aspir 81, Aspir-Low, Bufferin, Easprin, Ecotrin, Ecpirin, Fasprin, Halfprin, Miniprin

  • DeviceResolute Integrity DES

    Resolute Integrity DES

  • DeviceCOBRA PzF

    Also known as: COBRA PzF coronary stent system

  • DrugDAPT

    At the discretion of the investigator as to which DAPT is administered (per local practice)

    Also known as: Dual Anti Platelet Therapy

06

What researchers measure

Primary outcomes

  1. Neointimal coverage of the stent as measured using OCT

    Neointimal coverage of the stent as measured using OCT

    Time frame: 1 month

  2. Neointimal coverage of the stent as measured using OCT

    Neointimal coverage of the stent as measured using OCT

    Time frame: 3 months

  3. Presence of thrombus formation as measured by OCT

    Presence of thrombus formation as measured by OCT

    Time frame: 1 month

  4. Presence of thrombus formation as measured by OCT

    Presence of thrombus formation as measured by OCT

    Time frame: 3 months

  5. Proportion of uncovered struts as measured by OCT

    Proportion of uncovered struts as measured by OCT

    Time frame: 1 month

  6. Proportion of uncovered struts as measured by OCT

    Proportion of uncovered struts as measured by OCT

    Time frame: 3 months

  7. Presence of Malopposed struts as measured by OCT

    Presence of Malopposed struts as measured by OCT

    Time frame: 1 month

  8. Presence of Malopposed struts as measured by OCT

    Presence of Malopposed struts as measured by OCT

    Time frame: 3 months

  9. In-stent neointimal thickness measured using OCT

    In-stent neointimal thickness measured using OCT

    Time frame: 1 month

  10. In-stent neointimal thickness measured by OCT

    In-stent neointimal thickness measured by OCT

    Time frame: 3 months

  11. Lumen area measured by OCT

    Lumen area measured by OCT

    Time frame: 1 month

  12. Lumen area measured by OCT

    Lumen area measured by OCT

    Time frame: 3 months

  13. Lumen Volume measured by OCT

    Lumen Volume measured by OCT

    Time frame: 1 month

  14. Lumen Volume measured by OCT

    Lumen Volume measured by OCT

    Time frame: 3 months

  15. Stent area measured by OCT

    Stent area measured by OCT

    Time frame: 1 month

  16. Stent area measured by OCT

    Stent area measured by OCT

    Time frame: 3 months

  17. Stent volume measured by OCT

    Stent volume measured by OCT

    Time frame: 1 month

  18. Stent volume measured by OCT

    Stent volume measured by OCT

    Time frame: 3 months

Other outcomes

  1. In-stent late loss measured by angiography

    In-stent late loss measured by angiography

    Time frame: 1 month

  2. In-stent late loss measured by angiography

    In-stent late loss measured by angiography

    Time frame: 3 months

  3. In-segment late loss measured by angiography

    In-segment late loss measured by angiography

    Time frame: 1 month

  4. In-segment late loss measured by angiography

    In-segment late loss measured by angiography

    Time frame: 3 months

  5. In-stent percent diameter stenosis measured by angiography

    In-stent percent diameter stenosis (%DS) measured by angiography

    Time frame: 1 month

  6. In-stent percent diameter stenosis measured by angiography

    In-stent percent diameter stenosis (%DS) measured by angiography

    Time frame: 3 months

  7. In-segment percent diameter stenosis measured by angiography

    In-segment percent diameter stenosis measured by angiography (%DS) (within the 5 mm margins proximal and distal to stent)

    Time frame: 1 month

  8. In-segment percent diameter stenosis measured by angiography

    In-segment percent diameter stenosis measured by angiography (%DS) (within the 5 mm margins proximal and distal to stent)

    Time frame: 3 months

  9. In-stent binary stenosis measured by angiography

    In-stent binary stenosis measured by angiography

    Time frame: 1 month

  10. In-stent binary stenosis measured by angiography

    In-stent binary stenosis measured by angiography(stenosis of \> 50% of the reference vessel diameter)

    Time frame: 3 months

  11. In-segment binary stenosis measured by angiography

    In-segment binary stenosis measured by angiography (stenosis of \> 50% of the reference vessel diameter)

    Time frame: 1 month

  12. In-segment binary stenosis measured by angiography

    In-segment binary stenosis measured by angiography (stenosis of \> 50% of the reference vessel diameter)

    Time frame: 3 months

  13. In-stent minimum lumen diameter measured by angiography

    In-stent minimum lumen diameter (MLD) measured by angiography

    Time frame: 1 month

  14. n-stent minimum lumen diameter measured by angiography

    In-stent minimum lumen diameter (MLD) measured by angiography

    Time frame: 3 months

  15. In-segment minimum lumen diameter (MLD) measured by angiography

    In-segment MLD measured by angiography

    Time frame: 1 month

  16. In-segment minimum lumen diameter (MLD) measured by angiography

    In-segment MLD measured by angiography

    Time frame: 3 months

  17. Longitudinal stent deformation measured by angiography

    Longitudinal stent deformation measured by angiography

    Time frame: 1 month

  18. Longitudinal stent deformation measured by angiography

    Longitudinal stent deformation measured by angiography

    Time frame: 3 months

  19. Presence of stent fracture measured by angiography

    Presence of stent fracture measured by angiography

    Time frame: 1 month

  20. Presence of stent fracture measured by angiography

    Presence of stent fracture measured by angiography

    Time frame: 3 months

  21. All Deaths

    All Deaths from any cause post index procedure

    Time frame: 1 month

  22. All Deaths

    All Deaths from any cause post index procedure

    Time frame: 6 months

  23. All Deaths

    All Deaths from any cause post index procedure

    Time frame: 12 months

  24. Cardiac Death

    Death due to cardiac cause post index procedure

    Time frame: 1 month

  25. Cardiac Death

    Death due to cardiac cause post index procedure

    Time frame: 6 months

  26. Cardiac Death

    Death due to cardiac cause post index procedure

    Time frame: 12 months

  27. Major Adverse Cardiac Events

    Major Adverse Cardiac Events (MACE) defined as cardiac death, MI (Q wave and non-Q wave), emergent bypass surgery, or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods

    Time frame: 1 month

  28. Major Adverse Cardiac Events

    Major Adverse Cardiac Events (MACE) defined as cardiac death, MI (Q wave and non-Q wave), emergent bypass surgery, or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods

    Time frame: 6 months

  29. Major Adverse Cardiac Events

    Major Adverse Cardiac Events (MACE) defined as cardiac death, MI (Q wave and non-Q wave), emergent bypass surgery, or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods

    Time frame: 12 months

  30. Myocardial Infarction

    Occurrence of myocardial infarction. Defined as either a Q wave MI (QWMI) or Non-Q wave MI (NQWMI).

    Time frame: 1 month

  31. Myocardial Infarction

    Occurrence of myocardial infarction. Defined as either a Q wave MI (QWMI) or Non-Q wave MI (NQWMI).

    Time frame: 6 months

  32. Myocardial Infarction

    Occurrence of myocardial infarction. Defined as either a Q wave MI (QWMI) or Non-Q wave MI (NQWMI).

    Time frame: 12 months

  33. Composite endpoint of cardiac death and MI

    Composite endpoint of Cardiac Death and MI

    Time frame: 1 month

  34. Composite endpoint of cardiac death and MI

    Composite endpoint of Cardiac Death and MI

    Time frame: 6 months

  35. Composite endpoint of cardiac death and MI

    Composite endpoint of Cardiac Death and MI

    Time frame: 12 months

  36. Clinically driven Target Lesion Revascularization

    Clinically driven TLR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.

    Time frame: 1 month

  37. Clinically driven Target Lesion Revascularization

    Clinically driven TLR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.

    Time frame: 6 months

  38. Clinically driven Target Lesion Revascularization

    Clinically driven TLR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.

    Time frame: 12 months

  39. Clinically driven target vessel revascularization

    Clinically driven TVR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself.

    Time frame: 1 month

  40. Clinically driven target vessel revascularization

    Clinically driven TVR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself.

    Time frame: 6 months

  41. Clinically driven target vessel revascularization

    Clinically driven TVR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself.

    Time frame: 12 months

  42. Occurrence of Stroke post index procedure

    Stroke (ischemic and hemorrhagic)

    Time frame: 1 month

  43. Occurrence of Stroke post index procedure

    Stroke (ischemic and hemorrhagic)

    Time frame: 6 months

  44. Occurrence of Stroke post index procedure

    Stroke (ischemic and hemorrhagic)

    Time frame: 12 months

  45. Acute success

    Device Success: Defined as the attainment of \< 30% final residual stenosis of the target lesion using only the COBRA PzFTM Coronary Stent System Lesion Success: Defined as the attainment of \< 30% final residual stenosis of the target lesion using any percutaneous method. Procedure Success: Attainment of \< 30% residual stenosis of the target lesion and no in-hospital MACE.

    Time frame: 30 days

  46. Bleeding or vascular complications

    Bleeding Complications: Defined as a procedure-related hemorrhagic event that requires a transfusion and/or surgical intervention. Vascular Complications may include pseudoaneurysm, arteriovenous fistula (AVF), peripheral ischemia/nerve injury, and vascular event requiring transfusion or surgical repair.

    Time frame: At time of hospital discharge (expected average to be within 2 days of index procedure

  47. Stent Thrombosis

    Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the patient has left the catheterization laboratory.

    Time frame: 3 months

07

Study locations

2 sites
  • Satakunta Central Hospital
    Pori, 28500, Finland
  • Heart Center, Turku University Hospital
    Turku, 20520, Finland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2014
First posted
Aug 25, 2014
Start
Jun 2014
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results delay requested
Jul 8, 2016
Last update
Oct 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02224235
Lead sponsor
CeloNova BioSciences, Inc.
Collaborators
ClinLogix. LLC
Responsible party
Sponsor
First posted
Aug 25, 2014
Start date
Jun 2014
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Oct 6, 2020

Study contacts

Pasi Karjalainen, MD, PhD
principal investigator · Satakunta Central Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion